WO1989001973A3 - Recombinant pox virus for immunization against tumor-associated antigens - Google Patents

Recombinant pox virus for immunization against tumor-associated antigens Download PDF

Info

Publication number
WO1989001973A3
WO1989001973A3 PCT/US1988/003032 US8803032W WO8901973A3 WO 1989001973 A3 WO1989001973 A3 WO 1989001973A3 US 8803032 W US8803032 W US 8803032W WO 8901973 A3 WO8901973 A3 WO 8901973A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated antigens
against tumor
pox virus
immunization against
recombinant pox
Prior art date
Application number
PCT/US1988/003032
Other languages
French (fr)
Other versions
WO1989001973A2 (en
Inventor
Dennis L Panicali
Rene Bernards
Original Assignee
Applied Biotechnology Inc
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Biotechnology Inc, Whitehead Biomedical Inst filed Critical Applied Biotechnology Inc
Publication of WO1989001973A2 publication Critical patent/WO1989001973A2/en
Publication of WO1989001973A3 publication Critical patent/WO1989001973A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.
PCT/US1988/003032 1987-09-02 1988-09-01 Recombinant pox virus for immunization against tumor-associated antigens WO1989001973A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9203687A 1987-09-02 1987-09-02
US092,036 1987-09-02

Publications (2)

Publication Number Publication Date
WO1989001973A2 WO1989001973A2 (en) 1989-03-09
WO1989001973A3 true WO1989001973A3 (en) 1989-03-23

Family

ID=22231039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/003032 WO1989001973A2 (en) 1987-09-02 1988-09-01 Recombinant pox virus for immunization against tumor-associated antigens

Country Status (2)

Country Link
CA (1) CA1341435C (en)
WO (1) WO1989001973A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12134653B2 (en) 2021-09-08 2024-11-05 Eucure (Beijing) Biopharma Co., Ltd Anti-CD40 antibodies and uses thereof

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
DE69032841T2 (en) * 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. RECOMBINANT CELLS FOR INFECTIVE THERAPIES AND HYPERPROLIEFERATIVE DISORDERS AND THEIR PRODUCTION
DK0474727T3 (en) 1989-05-19 1998-01-12 Genentech Inc HER2 extracellular domain
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
JP3208427B2 (en) * 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド Detection and quantification of neu-related proteins in human biological fluids
CA2067821A1 (en) * 1989-10-24 1991-04-25 Cetus Oncology Corporation Infective drug delivery system using recombinant retroviral vectors
CA2040099A1 (en) * 1990-05-01 1991-11-02 Mariano Barbacid Tyrosine kinase negative trkb
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
DK0584266T3 (en) * 1991-05-06 2003-12-29 Us Gov Health & Human Serv Recombinant virus expressing carcino embryonic antigen and methods for its use
US5545533A (en) * 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
DE4205148A1 (en) * 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh MONOCLONAL ANTIBODY AGAINST C-KIT
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
WO1995014091A2 (en) 1993-11-18 1995-05-26 Chiron Viagene, Inc. Compositions and methods for utilizing conditionally lethal genes
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
ES2301178T3 (en) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic RECOMBINANT ALFAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACROMOLECULAR SYNTHESIS.
WO1998000554A1 (en) 1996-07-03 1998-01-08 Genetics Institute, Inc. Protease fmh-1, an ice/ced-like protease
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
EP1025212B1 (en) 1997-10-14 2007-09-26 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
ATE476508T1 (en) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic NEISSERIAL ANTIGENS
EP1042360A2 (en) 1997-12-24 2000-10-11 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
BR9906927A (en) 1998-01-14 2001-11-20 Chiron Spa Neisseria meningitidis proteins
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1792988A3 (en) 1998-03-18 2007-08-22 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
BR9910089A (en) 1998-05-01 2004-06-08 Chiron Corp Compositions and antigens of neisseria meningitidis
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ATE386804T1 (en) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic GENES WITH ALTERED EXPRESSION IN METASTATIC BREAST OR COLON CANCER CELLS
GB2370573A (en) * 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
GB2347932B (en) * 1998-11-18 2003-05-07 Oxford Biomedica Ltd Vectors for the delivery of 5T4 antigen
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
ATE469222T1 (en) 1998-12-08 2010-06-15 Corixa Corp COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CHLAMYDIA INFECTIONS
WO2000036118A2 (en) 1998-12-16 2000-06-22 Chiron Corporation HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
NZ514818A (en) 1999-04-02 2004-04-30 Corixa Corp Compounds and methods for therapy and diagnosis of lung cancer
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
DK1248647T3 (en) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
PL209127B1 (en) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Tumour-specific animal proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60134134D1 (en) 2000-05-19 2008-07-03 Corixa Corp PROPHYLACTIC AND THERAPEUTIC TREATMENT OF TEN WITH COMPOUNDS BASED ON MONOSACCHARIDES
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
JP5139618B2 (en) 2000-06-20 2013-02-06 コリクサ コーポレイション Mycobacterium tuberculosis fusion protein
ATE396265T1 (en) 2000-06-28 2008-06-15 Corixa Corp COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2004525620A (en) 2001-01-17 2004-08-26 トルビオン・ファーマシューティカルズ・インコーポレイテッド Binding domain-immunoglobulin fusion protein
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
ATE494907T1 (en) 2002-07-18 2011-01-15 Univ Washington PHARMACEUTICAL COMPOSITIONS CONTAINING IMMUNOLOGICALLY ACTIVE HERPES SIMPLEX VIRUS PROTEIN FRAGMENTS
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
RU2544850C2 (en) 2003-01-06 2015-03-20 Корикса Корпорейшн Some amino alkyl glucose aminide phosphate derivatives and thereof application
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005007673A2 (en) 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
KR101222281B1 (en) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 Novel galectin 9 modification protein and use thereof
ATE481645T1 (en) 2004-07-14 2010-10-15 Univ California BIOMARRKERS FOR EARLY DETECTION OF OVARIAL CARCINOMA
EP1789552A2 (en) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
CA2580103C (en) 2004-09-22 2021-11-16 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
CA2602637A1 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
NZ562729A (en) 2005-04-29 2009-10-30 Infectious Disease Res Inst Id Novel method for preventing or treating M tuberculosis infection using Mtb72f fusion proteins
BRPI0613770A2 (en) 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anti-cd26 antibodies and methods of use of these
SI1912675T1 (en) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc B-cell reduction using cd37-specific and cd20-specific binding molecules
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
KR101571027B1 (en) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Single-chain multivalent binding proteins with effector function
PL2468300T3 (en) 2006-09-26 2018-04-30 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
ES2725450T3 (en) 2007-07-02 2019-09-24 Etubics Corp Methods and compositions for the production of an adenoviral vector for use in multiple vaccinations
JP2011516078A (en) 2008-04-10 2011-05-26 セル・シグナリング・テクノロジー・インコーポレイテツド Compositions and methods for detecting EGFR mutations in cancer
MX2010011057A (en) 2008-04-11 2010-11-12 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof.
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN102869372B (en) 2010-01-27 2016-01-20 葛兰素史密丝克莱恩生物有限公司 Modified tuberculosis antigen
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
WO2012154994A2 (en) 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
CN103608030A (en) 2011-06-21 2014-02-26 昂科发克特公司 Compositions and methods for therapy and diagnosis of cancer
KR20140063747A (en) 2011-08-29 2014-05-27 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Use of hdl-related molecules to treat and prevent proinflammatory conditions
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
EP2844282B1 (en) 2012-05-04 2019-06-12 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
ES2787455T3 (en) 2012-05-16 2020-10-16 Immune Design Corp HSV-2 vaccines
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014144521A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
CN105392882A (en) 2013-04-19 2016-03-09 加利福尼亚大学董事会 Lone star virus
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
WO2015003003A1 (en) 2013-07-01 2015-01-08 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2986319A1 (en) 2014-06-17 2015-12-23 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
JP2017521654A (en) 2014-06-27 2017-08-03 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Compositions and methods for detecting human pegivirus 2 (HPgV-2)
JP2018511655A (en) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Immunogenic compositions for use in vaccination against Bordetella
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
EP3405212B1 (en) 2016-01-19 2020-07-08 Pfizer Inc Cancer vaccines
CN109310773B (en) 2016-05-16 2022-04-26 传染病研究所 Formulations containing TLR agonists and methods of use
IL311086A (en) 2016-06-01 2024-04-01 Access To Advanced Health Inst Nanoalum particles containing a sizing agent
EP3651792A1 (en) 2017-07-11 2020-05-20 Pfizer Inc Immunogenic compositions comprising cea muc1 and tert
EP3661555A4 (en) 2017-08-01 2021-07-14 Ab Studio Inc. Bispecific antibodies and uses thereof
JP7155270B2 (en) 2017-09-21 2022-10-18 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド Anti-CTLA4 antibody and use thereof
KR102634374B1 (en) 2017-11-24 2024-02-06 유큐(베이징) 바이오파마 코., 엘티디 Anti-OX40 antibodies and uses thereof
US11912736B2 (en) 2018-02-21 2024-02-27 The University Of Montana Diaryl trehalose compounds and uses thereof
CA3091502A1 (en) 2018-02-23 2019-08-29 Eucure (Beijing) Biopharma Co., Ltd Anti-pd-1 antibodies and uses thereof
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
JP7212138B2 (en) 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド Anti-CD40 antibody and uses thereof
SG11202102335YA (en) 2018-09-12 2021-04-29 Eucure Beijing Biopharma Co Ltd Anti-tnfrsf9 antibodies and uses thereof
JP7469305B2 (en) 2018-11-19 2024-04-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド Anti-PD-1 antibodies and uses thereof
WO2020169022A1 (en) 2019-02-18 2020-08-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animals with humanized immunoglobulin locus
AU2020278777A1 (en) 2019-05-23 2021-12-16 The University Of Montana Vaccine adjuvants based on TLR receptor ligands
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals Beijing Co Ltd Genetically modified non-human animals with common light chain immunoglobulin locus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
J. Gen. Virol. vol. 67, no. 10 (GB) M. Mackett et al.: "Review Article - Vaccinia virus expression vectors" pages 2067-2082 *
Nature, vol. 319, 16 January 1986, C.I. Bargmann et al.: "The neu oncogene encodes an epidermal growth factor receptor-related protein" pages 226-230 *
Nature, vol. 319, 16 January 1986, T. Yamamoto et al.: "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor" pages 230-234 *
Nature, vol. 319, 27 Februay 1986, D. Martin-Zanca et al.: "A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences" pages 743-748 *
Nature, vol. 326, 30 April 1987, R. Lathe et al.: "Tumour prevention and rejection with recombinant vaccinia" pages 878-880 *
Proc. Natl. Acad. Sci, USA, vol. 83, September 1986 (US) L. Nagarajan et al.: "The human c-ros gene (ROS) is located at chromosome region 6q16-6q22" pages 6568-6572 *
Proc. Natl. Acad. Sci, USA, vol. 84, October 1987 (US) R. Bernards et al.: "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector" pages 6854-6858 *
The EMBO Journal, vol. 6, no. 11, (GB) Y. Yarden et al.: "Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand" pages 3341-3351 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12134653B2 (en) 2021-09-08 2024-11-05 Eucure (Beijing) Biopharma Co., Ltd Anti-CD40 antibodies and uses thereof

Also Published As

Publication number Publication date
CA1341435C (en) 2003-07-29
WO1989001973A2 (en) 1989-03-09

Similar Documents

Publication Publication Date Title
WO1989001973A3 (en) Recombinant pox virus for immunization against tumor-associated antigens
CA2261989A1 (en) Recombinant pox virus for immunization against tumor-associated antigens
WO1995029193A3 (en) Melanoma antigens
EP1335023A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
EP0904393A4 (en) Parapoxvirus vectors
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
EP0332424A3 (en) Chimeric antibodies directed against human carcinoembryonic antigen
AR243080A1 (en) A procedure for obtaining an immunogenic complex of proteins, antigens or peptides, with water-repelling regions and bisdesmosidic regions with water-repelling regions.
NO892251D0 (en) PROCEDURE FOR THE PREPARATION OF COCOCOIDOSE VACCINE BY RECOMBINANT TECHNIQUES.
AU2445888A (en) Recombinant fowlpox virus, vectors for the expression of heterologous proteins and vaccines for poultry derived from this virus
GB9209718D0 (en) Hcg-hlh receptor and hcg-hlh receptor-hch complex as antigens,antibodies thereto and contraceptive vaccine
CA2272338A1 (en) Immunization of infants
CA2101463A1 (en) Recombinant adenovirus vaccines
IT1147844B (en) MALARIA ANTIGEN, PROCEDURE FOR ITS PREPARATION AND VACCINE WITH IT OBTAINED
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
CA2135630A1 (en) Hiv protein epitopes immunologically homologous to hla
EP0327000A3 (en) Gene fragments coding for the variable region of an anti-hiv antibody, chimeric anti-hiv antibodies expressed using the same, and process for their preparation
DK0431327T4 (en) Synthetic vaccine for specific induction of cytotoxic T lymphocytes
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
AU3670697A (en) Recombinant pox virus for immunization against tumor-associated antigens
NZ223624A (en) Peptide immunogen from streptococcus mutans, vaccines and antibodies
CA2176929A1 (en) Vaccine against mumps containing a jeryl-lynn virus strain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE